ESC Premium Access

Efficacy and safety of direct oral anticoagulants with diabetes and nonvalvular atrial fibrillation: a systematic review and meta-analysis

Congress Session

About the speaker

Doctor Goncalo Costa

Centro Hospitalar Universitario de Coimbra, Coimbra (Portugal)
0 follower

57 more presentations in this session

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Speaker: Doctor J. Borovac (Split, HR)

Thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Speaker: Doctor A. KANWAL (Valhalla, US)

Thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Speaker: Doctor K. Dzaurova (Moscow, RU)

Thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Access the full session

Pharmacology and pharmacotherapy e-posters

Speakers: Doctor G. Costa, Doctor J. Borovac, Doctor A. KANWAL, Doctor K. Dzaurova, Mrs A. Boulmpou...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

COVID-19 and ACS admissions: lessons from the UK.

27 August 2021

ESC Premium Access

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

27 August 2021

ESC Premium Access

Net clinical benefit of direct oral anticoagulants in very elderly and high bleeding risk patients with atrial fibrillation who are often excluded from oral anticoagulation therapy: a nationwide popul

27 August 2021

This platform is supported by

logo Novo Nordisk